Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-06-19

AUTHORS

Marya D Zilberberg, Smita Kothari, Andrew F Shorr

ABSTRACT

IntroductionRecent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Echinocandins, a new class of antifungal agents, are effective against resistant candidal species. As delaying appropriate antifungal coverage leads to increased mortality, we evaluated the cost-effectiveness of 100 mg daily empiric micafungin (MIC) vs. 400 mg daily fluconazole (FLU) for suspected intensive care unit-acquired candidemia (ICU-AC) among septic patients.MethodsWe designed a decision model with inputs from the literature in a hypothetical 1000-patient cohort with suspected ICU-AC treated empirically with either MIC or FLU or no treatment accompanied by a watchful waiting strategy. We examined the differences in the number of survivors, acquisition costs of antifungals, and lifetime costs among survivors in the cohort under each scenario, and calculated cost per quality adjusted life year (QALY). We conducted Monte Carlo simulations and sensitivity analyses to determine the stability of our estimates.ResultsIn the base case analysis, assuming ICU-AC attributable mortality of 0.40 and a 52% relative risk reduction in mortality with appropriate timely therapy, compared with FLU (total deaths 31), treatment with MIC (total deaths 27) would result in four fewer deaths at an incremental cost/death averted of $61,446. Similarly, in reference case, incremental cost-effectiveness of MIC over FLU was $34,734 (95% confidence interval $26,312 to $49,209) per QALY. The estimates were most sensitive to the QALY adjustment factor and the risk of candidemia among septic patients.ConclusionsGiven the increasing likelihood of azole resistance among candidal isolates, empiric treatment of ICU-AC with 100 mg daily MIC is a cost-effective alternative to FLU. More... »

PAGES

r94

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/cc7924

DOI

http://dx.doi.org/10.1186/cc7924

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004034716

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19545361


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antifungal Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Candidiasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decision Trees", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Fungal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Echinocandins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluconazole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fungemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intensive Care Units", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Micafungin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Econometric", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Monte Carlo Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "EviMed Research Group, LLC, PO Box 303, 01032, Goshen, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "School of Public Health and Health Sciences, University of Massachusetts, Arnold House,715 North Pleasant Street, 01003, Amherst, MA, USA", 
            "EviMed Research Group, LLC, PO Box 303, 01032, Goshen, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zilberberg", 
        "givenName": "Marya D", 
        "id": "sg:person.01101364260.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101364260.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Astellas Pharma US, Inc., 3 Parkway North, 60015, Deerfield, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.423286.9", 
          "name": [
            "Health Economics and Outcomes Research, Astellas Pharma US, Inc., 3 Parkway North, 60015, Deerfield, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kothari", 
        "givenName": "Smita", 
        "id": "sg:person.0637752113.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637752113.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care, Washington Hospital Center, 100 Irving Street NW, 20010, Washington, DC, USA", 
          "id": "http://www.grid.ac/institutes/grid.415235.4", 
          "name": [
            "Division of Pulmonary and Critical Care, Washington Hospital Center, 100 Irving Street NW, 20010, Washington, DC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shorr", 
        "givenName": "Andrew F", 
        "id": "sg:person.0606505446.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606505446.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/cc6766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036413742", 
          "https://doi.org/10.1186/cc6766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200363200-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017599941", 
          "https://doi.org/10.2165/00003495-200363200-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-003-2121-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013264187", 
          "https://doi.org/10.1007/s00134-003-2121-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-001-1143-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027018720", 
          "https://doi.org/10.1007/s00134-001-1143-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01712153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002298120", 
          "https://doi.org/10.1007/bf01712153"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-06-19", 
    "datePublishedReg": "2009-06-19", 
    "description": "IntroductionRecent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Echinocandins, a new class of antifungal agents, are effective against resistant candidal species. As delaying appropriate antifungal coverage leads to increased mortality, we evaluated the cost-effectiveness of 100 mg daily empiric micafungin (MIC) vs. 400 mg daily fluconazole (FLU) for suspected intensive care unit-acquired candidemia (ICU-AC) among septic patients.MethodsWe designed a decision model with inputs from the literature in a hypothetical 1000-patient cohort with suspected ICU-AC treated empirically with either MIC or FLU or no treatment accompanied by a watchful waiting strategy. We examined the differences in the number of survivors, acquisition costs of antifungals, and lifetime costs among survivors in the cohort under each scenario, and calculated cost per quality adjusted life year (QALY). We conducted Monte Carlo simulations and sensitivity analyses to determine the stability of our estimates.ResultsIn the base case analysis, assuming ICU-AC attributable mortality of 0.40 and a 52% relative risk reduction in mortality with appropriate timely therapy, compared with FLU (total deaths 31), treatment with MIC (total deaths 27) would result in four fewer deaths at an incremental cost/death averted of $61,446. Similarly, in reference case, incremental cost-effectiveness of MIC over FLU was $34,734 (95% confidence interval $26,312 to $49,209) per QALY. The estimates were most sensitive to the QALY adjustment factor and the risk of candidemia among septic patients.ConclusionsGiven the increasing likelihood of azole resistance among candidal isolates, empiric treatment of ICU-AC with 100 mg daily MIC is a cost-effective alternative to FLU.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/cc7924", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1117766", 
        "issn": [
          "1364-8535", 
          "1466-609X"
        ], 
        "name": "Critical Care", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "empiric treatment", 
      "septic patients", 
      "candidal species", 
      "watchful waiting strategy", 
      "risk of candidemia", 
      "incidence of hospitalization", 
      "relative risk reduction", 
      "base-case analysis", 
      "antifungal coverage", 
      "daily fluconazole", 
      "candidal isolates", 
      "number of survivors", 
      "attributable mortality", 
      "death averted", 
      "timely therapy", 
      "candidemia", 
      "life years", 
      "epidemiologic literature", 
      "micafungin", 
      "patients", 
      "fluconazole", 
      "mortality", 
      "waiting strategy", 
      "lifetime costs", 
      "azole resistance", 
      "treatment", 
      "antifungal agents", 
      "risk reduction", 
      "cohort", 
      "survivors", 
      "acquisition costs", 
      "cost-effective alternative", 
      "sepsis", 
      "hospitalization", 
      "ICU", 
      "therapy", 
      "QALY", 
      "MethodsWe", 
      "incidence", 
      "ResultsIn", 
      "echinocandins", 
      "averted", 
      "death", 
      "antifungals", 
      "ConclusionsGiven", 
      "risk", 
      "isolates", 
      "azoles", 
      "years", 
      "agents", 
      "literature", 
      "factors", 
      "differences", 
      "cases", 
      "likelihood", 
      "sensitivity analysis", 
      "alternative", 
      "reduction", 
      "analysis", 
      "resistance", 
      "case analysis", 
      "adjustment factors", 
      "quality", 
      "strategies", 
      "new class", 
      "number", 
      "estimates", 
      "coverage", 
      "cost", 
      "face", 
      "decision model", 
      "species", 
      "model", 
      "class", 
      "input", 
      "stability", 
      "reference case", 
      "scenarios", 
      "Monte Carlo simulations", 
      "Carlo simulations", 
      "model simulations", 
      "simulations"
    ], 
    "name": "Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation", 
    "pagination": "r94", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004034716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/cc7924"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19545361"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/cc7924", 
      "https://app.dimensions.ai/details/publication/pub.1004034716"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_478.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/cc7924"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/cc7924'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/cc7924'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/cc7924'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/cc7924'


 

This table displays all metadata directly associated to this object as RDF triples.

256 TRIPLES      21 PREDICATES      130 URIs      117 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/cc7924 schema:about N041e8f25659f484e82fe757eae4e3e03
2 N1164ead01b5c4d7aa47c99b248fa9e2b
3 N17d24cb83e504a439fd44fb396a4e763
4 N4aca2cfd909a4c5d8e91b3e7a4333171
5 N58897b9d2b8c4170b802eb4a984b416d
6 N5c7f81cf614741c7b03854a0ac666661
7 N6e6ddc74b5794b8885da23345a628578
8 N71c48321516445ff8616fbdd4d7d2a71
9 N7bd52c431ee843fa9e005aa023d3a12f
10 N91dfc1e94c7f4880ae7f02d85b25f81c
11 Nbfc4f97ec8bd4088b82bae869830a97f
12 Ncc059d44c4ba44b492e03e16d7198bb3
13 Nd1416c884efb48499dcc040f856f3695
14 Nd1c59856726f4c41a81be773ef4e359f
15 Nd74f0f7665fd44bf8f022776165a760a
16 Nd878176e9816462da596349bf4f65831
17 Ne20ceaee5f16427fa1b8752c63960c1a
18 Nf65cc4ca1daf475aa83f0c68c6971068
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author N2eeaa709109049c4bbbdae7b8617be35
22 schema:citation sg:pub.10.1007/bf01712153
23 sg:pub.10.1007/s00134-001-1143-z
24 sg:pub.10.1007/s00134-003-2121-4
25 sg:pub.10.1186/cc6766
26 sg:pub.10.2165/00003495-200363200-00001
27 schema:datePublished 2009-06-19
28 schema:datePublishedReg 2009-06-19
29 schema:description IntroductionRecent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Echinocandins, a new class of antifungal agents, are effective against resistant candidal species. As delaying appropriate antifungal coverage leads to increased mortality, we evaluated the cost-effectiveness of 100 mg daily empiric micafungin (MIC) vs. 400 mg daily fluconazole (FLU) for suspected intensive care unit-acquired candidemia (ICU-AC) among septic patients.MethodsWe designed a decision model with inputs from the literature in a hypothetical 1000-patient cohort with suspected ICU-AC treated empirically with either MIC or FLU or no treatment accompanied by a watchful waiting strategy. We examined the differences in the number of survivors, acquisition costs of antifungals, and lifetime costs among survivors in the cohort under each scenario, and calculated cost per quality adjusted life year (QALY). We conducted Monte Carlo simulations and sensitivity analyses to determine the stability of our estimates.ResultsIn the base case analysis, assuming ICU-AC attributable mortality of 0.40 and a 52% relative risk reduction in mortality with appropriate timely therapy, compared with FLU (total deaths 31), treatment with MIC (total deaths 27) would result in four fewer deaths at an incremental cost/death averted of $61,446. Similarly, in reference case, incremental cost-effectiveness of MIC over FLU was $34,734 (95% confidence interval $26,312 to $49,209) per QALY. The estimates were most sensitive to the QALY adjustment factor and the risk of candidemia among septic patients.ConclusionsGiven the increasing likelihood of azole resistance among candidal isolates, empiric treatment of ICU-AC with 100 mg daily MIC is a cost-effective alternative to FLU.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf N3041e058e1104aa086c8876aa21cef62
33 Nb4325193ed03451281b7215eaecf9083
34 sg:journal.1117766
35 schema:keywords Carlo simulations
36 ConclusionsGiven
37 ICU
38 MethodsWe
39 Monte Carlo simulations
40 QALY
41 ResultsIn
42 acquisition costs
43 adjustment factors
44 agents
45 alternative
46 analysis
47 antifungal agents
48 antifungal coverage
49 antifungals
50 attributable mortality
51 averted
52 azole resistance
53 azoles
54 base-case analysis
55 candidal isolates
56 candidal species
57 candidemia
58 case analysis
59 cases
60 class
61 cohort
62 cost
63 cost-effective alternative
64 coverage
65 daily fluconazole
66 death
67 death averted
68 decision model
69 differences
70 echinocandins
71 empiric treatment
72 epidemiologic literature
73 estimates
74 face
75 factors
76 fluconazole
77 hospitalization
78 incidence
79 incidence of hospitalization
80 input
81 isolates
82 life years
83 lifetime costs
84 likelihood
85 literature
86 micafungin
87 model
88 model simulations
89 mortality
90 new class
91 number
92 number of survivors
93 patients
94 quality
95 reduction
96 reference case
97 relative risk reduction
98 resistance
99 risk
100 risk of candidemia
101 risk reduction
102 scenarios
103 sensitivity analysis
104 sepsis
105 septic patients
106 simulations
107 species
108 stability
109 strategies
110 survivors
111 therapy
112 timely therapy
113 treatment
114 waiting strategy
115 watchful waiting strategy
116 years
117 schema:name Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation
118 schema:pagination r94
119 schema:productId N790424ca39dc46f88a29bf6ddd34107f
120 Na65f9e7b798d4a668364ca8e07b8bf0d
121 Nb43f4ea78c954972bcc0b0a51f5b2801
122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004034716
123 https://doi.org/10.1186/cc7924
124 schema:sdDatePublished 2022-12-01T06:27
125 schema:sdLicense https://scigraph.springernature.com/explorer/license/
126 schema:sdPublisher N6bdb8995410546848a3de12dc263d0a0
127 schema:url https://doi.org/10.1186/cc7924
128 sgo:license sg:explorer/license/
129 sgo:sdDataset articles
130 rdf:type schema:ScholarlyArticle
131 N041e8f25659f484e82fe757eae4e3e03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Incidence
133 rdf:type schema:DefinedTerm
134 N0685e579260743328e0be0e92811ca9c rdf:first sg:person.0637752113.13
135 rdf:rest N31852480b6124d70a168d001a7ddcc5d
136 N1164ead01b5c4d7aa47c99b248fa9e2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Quality-Adjusted Life Years
138 rdf:type schema:DefinedTerm
139 N17d24cb83e504a439fd44fb396a4e763 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Models, Econometric
141 rdf:type schema:DefinedTerm
142 N2eeaa709109049c4bbbdae7b8617be35 rdf:first sg:person.01101364260.43
143 rdf:rest N0685e579260743328e0be0e92811ca9c
144 N3041e058e1104aa086c8876aa21cef62 schema:issueNumber 3
145 rdf:type schema:PublicationIssue
146 N31852480b6124d70a168d001a7ddcc5d rdf:first sg:person.0606505446.70
147 rdf:rest rdf:nil
148 N4aca2cfd909a4c5d8e91b3e7a4333171 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antifungal Agents
150 rdf:type schema:DefinedTerm
151 N58897b9d2b8c4170b802eb4a984b416d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Echinocandins
153 rdf:type schema:DefinedTerm
154 N5c7f81cf614741c7b03854a0ac666661 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 N6bdb8995410546848a3de12dc263d0a0 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 N6e6ddc74b5794b8885da23345a628578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Micafungin
161 rdf:type schema:DefinedTerm
162 N71c48321516445ff8616fbdd4d7d2a71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Cost-Benefit Analysis
164 rdf:type schema:DefinedTerm
165 N790424ca39dc46f88a29bf6ddd34107f schema:name doi
166 schema:value 10.1186/cc7924
167 rdf:type schema:PropertyValue
168 N7bd52c431ee843fa9e005aa023d3a12f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Drug Resistance, Fungal
170 rdf:type schema:DefinedTerm
171 N91dfc1e94c7f4880ae7f02d85b25f81c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Fungemia
173 rdf:type schema:DefinedTerm
174 Na65f9e7b798d4a668364ca8e07b8bf0d schema:name pubmed_id
175 schema:value 19545361
176 rdf:type schema:PropertyValue
177 Nb4325193ed03451281b7215eaecf9083 schema:volumeNumber 13
178 rdf:type schema:PublicationVolume
179 Nb43f4ea78c954972bcc0b0a51f5b2801 schema:name dimensions_id
180 schema:value pub.1004034716
181 rdf:type schema:PropertyValue
182 Nbfc4f97ec8bd4088b82bae869830a97f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Drug Costs
184 rdf:type schema:DefinedTerm
185 Ncc059d44c4ba44b492e03e16d7198bb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Candidiasis
187 rdf:type schema:DefinedTerm
188 Nd1416c884efb48499dcc040f856f3695 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Lipopeptides
190 rdf:type schema:DefinedTerm
191 Nd1c59856726f4c41a81be773ef4e359f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Monte Carlo Method
193 rdf:type schema:DefinedTerm
194 Nd74f0f7665fd44bf8f022776165a760a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Intensive Care Units
196 rdf:type schema:DefinedTerm
197 Nd878176e9816462da596349bf4f65831 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Cross Infection
199 rdf:type schema:DefinedTerm
200 Ne20ceaee5f16427fa1b8752c63960c1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Fluconazole
202 rdf:type schema:DefinedTerm
203 Nf65cc4ca1daf475aa83f0c68c6971068 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Decision Trees
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1117766 schema:issn 1364-8535
213 1466-609X
214 schema:name Critical Care
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01101364260.43 schema:affiliation grid-institutes:None
218 schema:familyName Zilberberg
219 schema:givenName Marya D
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101364260.43
221 rdf:type schema:Person
222 sg:person.0606505446.70 schema:affiliation grid-institutes:grid.415235.4
223 schema:familyName Shorr
224 schema:givenName Andrew F
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606505446.70
226 rdf:type schema:Person
227 sg:person.0637752113.13 schema:affiliation grid-institutes:grid.423286.9
228 schema:familyName Kothari
229 schema:givenName Smita
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637752113.13
231 rdf:type schema:Person
232 sg:pub.10.1007/bf01712153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002298120
233 https://doi.org/10.1007/bf01712153
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s00134-001-1143-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1027018720
236 https://doi.org/10.1007/s00134-001-1143-z
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s00134-003-2121-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013264187
239 https://doi.org/10.1007/s00134-003-2121-4
240 rdf:type schema:CreativeWork
241 sg:pub.10.1186/cc6766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036413742
242 https://doi.org/10.1186/cc6766
243 rdf:type schema:CreativeWork
244 sg:pub.10.2165/00003495-200363200-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017599941
245 https://doi.org/10.2165/00003495-200363200-00001
246 rdf:type schema:CreativeWork
247 grid-institutes:None schema:alternateName EviMed Research Group, LLC, PO Box 303, 01032, Goshen, MA, USA
248 schema:name EviMed Research Group, LLC, PO Box 303, 01032, Goshen, MA, USA
249 School of Public Health and Health Sciences, University of Massachusetts, Arnold House,715 North Pleasant Street, 01003, Amherst, MA, USA
250 rdf:type schema:Organization
251 grid-institutes:grid.415235.4 schema:alternateName Division of Pulmonary and Critical Care, Washington Hospital Center, 100 Irving Street NW, 20010, Washington, DC, USA
252 schema:name Division of Pulmonary and Critical Care, Washington Hospital Center, 100 Irving Street NW, 20010, Washington, DC, USA
253 rdf:type schema:Organization
254 grid-institutes:grid.423286.9 schema:alternateName Health Economics and Outcomes Research, Astellas Pharma US, Inc., 3 Parkway North, 60015, Deerfield, IL, USA
255 schema:name Health Economics and Outcomes Research, Astellas Pharma US, Inc., 3 Parkway North, 60015, Deerfield, IL, USA
256 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...